Building Better People: The Truths and Myths of Gene Therapy

By Murray, Bruce | The Quill, June 2001 | Go to article overview
Save to active project

Building Better People: The Truths and Myths of Gene Therapy

Murray, Bruce, The Quill

Biotechnology represents one of the most technically challenging issues for journalists to cover in the news. Not only is the subject complex, but rapid changes and advances in the various biotech fields provide an additional challenge for journalists. The Foundation for American Communications recently held a conference at the Harrison Conference Center near Chicago to assist reporters in their daunting assignment. FACS brought together a faculty of top researchers in the field, university professors, clinical researchers, medical ethicists and industry experts. The group covered subjects ranging from stem cell research, gene therapy and cloning to the related law and ethics. Provided here is coverage of the discussion of gene therapy, its history and regulations.

The sound of terms like "gene therapy" and "recombinant DNA technology" might conjure up negative images of eugenics, clandestine government experiments and conspiracies. For that reason, Dr. Nelson Wivel, deputy director of the Institute of Gene Therapy at the University of Pennsylvania School of Medicine, favors a public oversight system that allows free access to the media and the rest of the general public. Wivel, former director of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC), is an expert on the history of gene therapy and its regulation. Wivel spoke at a recent FACS biotech conference.

"As long as the public has access to open discussion of new issues in gene therapy, and as long as the press reports those discussions, there is reason to be optimistic that the science will eventually go forward," Wivel said.

Researchers have been contemplating gene therapy for the past 50 years. The first clinical gene therapy trial took place in 1990 with the study of a patient with severe combined immune deficiency (SCID).

"The patient was not cured, but proof of principle was established in that successful gene transfer was demonstrated," Wivel said.

The first evidence of successful gene therapy was reported in 2000 by French researcher Alain Fisher in the treatment of SCID. The DNA research community was rocked in 1999 when Jesse Gelsinger died during gene therapy administered at the University of Pennsylvania School of Medicine.

Since then, researchers and regulators have regrouped and reorganized, and research is proceeding again on a more cautious course.


Wivel described gene therapy as the insertion of functioning genes into a person's cells, either to correct an inborn genetic error or to impart a new function to the cell. Somatic cell gene therapy, as it is called, is an application of recombinant DNA technology. Somatic cells are non-reproductive cells, as opposed to germ-line cells which are reproductive cells.

Recombinant DNA refers to DNA molecules in which sequences which are not naturally contiguous have been placed next to each other by in vitro manipulations. The different sequences within a recombinant DNA molecule will frequently have come from entirely different organisms.

A critical component of gene therapy is the delivery of the genes to the body. Unlike typical drugs (Wivel considers gene therapy akin to drug therapy), genes cannot simply be taken like a pill. Genes have to be inserted into a cell's nucleus. During the 1960s, researchers contemplated the use of viruses, normally an enemy, as an agent for delivery of genes. Viruses replicate themselves by invading a cell's DNA and inserting their own genetic code.

"Viruses are the smartest cell parasites that we know about: They're clever; they know how to replicate; and they can be re-engineered to make them non-infectious," Wivel said.

In gene therapy, the desired genes must first be isolated from a normal chromosome; and then those genes are attached to the DNA of a harmless virus, which is then let loose on the patient.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Building Better People: The Truths and Myths of Gene Therapy


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?